Safety of Once-Daily Oxymetazoline HCl Ophthalmic Solution, 0.1% in Patients with Acquired Blepharoptosis: Results from Four Randomized, Double-Masked Clinical Trials

Safety of Once-Daily Oxymetazoline HCl Ophthalmic Solution, 0.1% in Patients with Acquired Blepharoptosis: Results from Four Randomized, Double-Masked Clinical Trials

David L Wirta,1 Michael S Korenfeld,2 Shane Foster,3 Robert Smyth-Medina,4 Jason Bacharach,5 Shane R Kannarr,6 Mark J Jaros,7 Charles B Slonim8 1Aesthetic Eye Care Institute & Eye Research Foundation, Newport Beach, CA, USA; 2Comprehensive Eye Care, Ltd., Washington, MO, USA; 3Athens Eye Car...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Wirta DL, Korenfeld MS, Foster S, Smyth-Medina R, Bacharach J, Kannarr SR, Jaros MJ, Slonim CB
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2021
Materias:
adrenergic agonist
adverse event
eye drop
intraocular pressure
müller’s muscle
pupil
topical
Ophthalmology
RE1-994
Acceso en línea:https://doaj.org/article/b902ef01813a410a8ed913930410b88d
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares